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SUMMARY
Introduction Desquamative interstitial pneumonia is one of the rarest idiopathic interstitial pneumo-
nias and the rarest form of smoking-related interstitial lung diseases. It was first described by Liebow 
in 1965. Histologically, it is characterized by the presence of eosinophilic macrophages uniformly filling 
airspaces which often contain a finely granular light-brown pigment that does not stain for hemosiderin. 
The alveolar walls are usually mildly thickened by fibrous tissue and infiltrated by a moderate number 
of lymphocytes.
Case Outline Our patient was a 56-year-old male, heavy smoker, with bilateral lung infiltrations of un-
known etiology and several months of discomfort in the form of dry cough and shortness of breath. Lung 
function tests showed a moderate restrictive ventilation disorder and a severe reduction of diffusing 
capacity. Since bronchoscopic specimens did not reveal lung lesion etiology, an open lung biopsy of the 
lower left pulmonary lobe was performed, and based on the obtained surgical material the pathohisto-
logically diagnosis of desquamative interstitial pneumonia was established. The patient was started on 
corticosteroid and immunosuppressive therapy, and he ceased smoking. At the last control examina-
tion, two years after the onset of symptoms, the patient was feeling well, and high-resolution computed 
tomography (HRCT) scan of the thorax showed regression of pathological changes.
Conclusion Although, as in our case, the majority of DIP patients improve on treatment, some patients 
still develop progressive irreversible fibrosis despite therapy.
keywords: desquamative interstitial pneumonia; interstitial lung disease; smoking; smokers; macro-
phages; smoking-related interstitial lung disease
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INTRODUCTION
Desquamative interstitial pneumonia (DIP) is 
one of the rarest idiopathic interstitial pneumo-
nias. Together with respiratory bronchiolitis-
interstitial lung disease (RB-ILD) and Langer-
hans cell histiocytosis it can be a part of smok-
ing related interstitial lung diseases (SR-ILD) 
[1]. It is characterized by the accumulation of 
macrophages in large numbers in the alveolar 
spaces associated with interstitial inflammation 
with or without fibrosis. The alveolar macro-
phages frequently contain a light brown pig-
ment which does not stain for hemosiderin, 
and because of their association with smoking 
they are called smoker’s macrophages. Lym-
phocytic infiltrate within the alveolar septa, 
often in the form of lymphoid nodules are 
common [1, 2]. Most cases of DIP are caused 
by cigarette smoking, but drugs (especially 
marijuana smoke) and other inhaled agents can 
also produce the same disease. Although the 
majority of DIP patients improve on treatment, 
some patients develop progressive irreversible 
fibrosis [2, 3].
CASE REPORT
A 56-year-old male patient, a painter, heavy 
smoker (2 packs per day/40 years), with sev-
eral months of discomfort in the form of dry 
cough and shortness of breath, fever and loss 
of body weight was admitted to hospital in 
May 2011. On physical examination digital 
clubbing and bilateral basal inspiratory crack-
les were present. Laboratory findings showed 
moderately elevated markers of inflammation 
(SE 80 mm/h, WBC 11.9×109/L, fibrinogen 
5 g/l). Lung test function revealed a moder-
ately restrictive ventilation disorder (FVC 2.87 
(68.8% predicted), TLC 5.4 (80% predicted)) 
and severe reduction of diffusion capacity (DL-
COSB 2.51 (26.4% predicted). Arterial blood 
gas analysis showed manifest partial respira-
tory insufficiency (PaO2 7.98, kPa, PaCO2 5.34, 
SaO2 91.6%). PaO2 dropped to 6.21 and kPa at 
minimal exertion (walking on a flat surface for 
6 minutes).
On CT scan of the thorax, bilateral areas of 
ground glass opacification, more pronounced 
dorsally were described (Figure 1). After first 
bronchoscopy, the etiology of lesions remained 
unknown. After second bronchoscopy, in ma-
terial obtained by transbronchial biopsy, areas 
of organizing pneumonia were revealed. Since 
this feature was nonspecific lung biopsy was 
performed.
Grossly, a resected specimen of the lower left 
pulmonary lobe taken during open lung biop-
sy procedure, 4×2 cm in dimensions, showed 
mildly thickened, blurred pleura. On cross sec-
tion, the lung parenchyma was dark-grey with 
reduced airiness (Figure 2).     
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The operative material was entirely histologically ex-
amined. The histological sections were stained by the rou-
tine hematoxilyne-eosin (HE) method and Perls Prussian 
Blue. On scanning magnification, the lung parenchyma 
had eosinophilic appearance due to the presence of a 
large number of eosinophilic macrophages uniformly fill-
ing airspaces (Figure 3). The macrophages had abundant 
eosinophilic cytoplasm, which often contained a finely 
granular light brown pigment. On Perls Prussian blue 
stain, this pigment within the cytoplasm of macrophages 
did not stain for hemosiderin as common in heavy smok-
ers (smokers’ macrophages). Alveolar walls were mildly 
thickened by fibrous tissue uniform in appearance and 
infiltrated by a moderate number of lymphocytes, scant 
numbers of plasma cells and rare eosinophils (Figure 4). 
Focally, within the alveoli a moderate numbers of multi-
nucleated macrophages were present. Macrophages were 
also present within the lumen of bronchioles whose walls 
were focally infiltrated with lymphocytes forming a respi-
ratory bronchiolitis-like feature (Figure 5). Focally, chronic 
inflammation was evident in the form of lymphoid follicles 
which were associated with respiratory bronchioles. The 
pleura showed slight thickening, and it was infiltrated with 
lymphocytes, plasma cells and rare eosinophils. Based on 
such microscopic findings, our diagnosis was DIP.
Immediately after diagnosis, the patient was introduced 
to oral corticosteroid therapy (prednisone 60 mg per day) 
Figure 5. Respiratory bronchiolitis-like picture: macrophages present 
within lumen of bronchioles whose walls are focally infiltrated with 
lymphocytes (H&E, ×200)
Figure 1. CT scan of the thorax: bilateral areas of ground glass opaci-
fication, more pronounced dorsally
Figure 2. Grossly, the lung tissue shows mildly thickened, blurred pleu-
ra, and on cross section parenchyma is dark-grey with reduced airiness
Figure 3. On scanning magnification, lung parenchyma shows eosino-
philic appearance due to the presence of a large number of eosino-
philic macrophages uniformly filling airspaces (H&E, ×50).
Figure 4. Macrophages with abundant eosinophilic cytoplasm, which 
often contain a finely granular light brown pigment. Alveolar walls are 
mildly thickened by fibrous tissue uniform in appearance and infil-
trated by a moderate number of lymphocytes (H&E, ×200).  
604
  
doi: 10.2298/SARH1410602L
Lovrenski A. et al. Desquamative Interstitial Pneumonia: A Case Report
and azathioprine (150 mg per day), as well as smoking 
cessation and ceased working in order to avoid further 
exposure to inhaled agents. The patient was released from 
hospital with regular follow-ups at our Institute. After six 
months of combined medicamentose therapy, azathioprine 
was excluded, and the treatment was carried on with low 
doses of oral corticosteroids within the next three months. 
In view of significant improvement at the follow-up and 
high-resolution computed tomography (HRCT) scan find-
ings, after 9-month therapy in terms of reduction of ac-
tive changes within the lung, further treatment was ceased. 
The patient was still under pulmonologist’s supervision. A 
year without treatment, the patient has been asymptomatic 
regarding the respiratory system, with a mild reduction 
of single-breath carbon-monoxide diffusing capacity of 
the lungs (DLCOSB 43% predicted) and without restrictive 
ventilation disorder. HRCT scan a year after the beginning 
of treatment revealed unchanged findings compared to 
the previous one.
DISCUSSION
Desquamative interstitial pneumonia (DIP) is an un-
common form of interstitial lung disease of unknown 
etiology. This entity, first described by Liebow in 1965, 
is characterized by diffuse interstitial infiltrates on chest 
roentgenogram, restrictive pulmonary function tests, and 
histology which demonstrates intraalveolar accumulation 
of macrophages [4].
According to Tazelaar et al. [2], approximately 90% of 
patients with DIP are smokers. On the other hand, in the 
series of Craig et al. [5] 40% of 20 patients were lifelong 
nonsmokers, and in an older series of Tubbs et al. [6] 
42% of 26 patients had no history of cigarette smoking. 
These findings suggest that DIP can occasionally be seen 
in nonsmokers in association with infections, and expo-
sure to occupational or environmental agents or drugs, 
including marijuana smoke [7]. Abraham and Hertzberg 
[8] explored biopsies of inorganic particles by scanning 
electron microscopy of 62 patohistologically-proven cases 
of DIP. They found inorganic particles in 17 patients; of 
these, seven had an occupational history compatible with 
exposure to inorganic particles, and high concentrations 
of inorganic particles in biopsy samples. Also, Moon et 
al. [9] described a case of DIP in a nonsmoking patient 
who was exposed to solder fumes at work. Craig et al. [5] 
showed that among 20 patients, two of eight nonsmokers 
and one patient in the smoker group, were exposed to oc-
cupational dust as fire-extinguisher powder, diesel fumes, 
and beryllium and copper dust, respectively. Lougheed et 
al. [10] described a series of five textile workers who were 
exposed to nylon filaments; two of these were ex-smokers 
and three never smoked. The reported cases of recurrent 
DIP following lung transplantation suggest a systemic 
pathogenesis of DIP. The relapse of this disease in a patient 
with lung transplant suggests that in certain individuals 
DIP represents a pulmonary manifestation of a systemic 
disease [11, 12].
Clinically, patients, most commonly middle age cigarette 
smokers, present with symptoms of dyspnea and nonpro-
ductive cough. Males are affected nearly twice as often as 
females [1, 2]. Physical examination demonstrates inspira-
tory crackles in 60% of patients and digital clubbing occurs 
in nearly one-half of patients. Pulmonary function testing 
reveals a predominantly restrictive defect, with reductions 
of 50% or more in diffusing capacity, with symmetrical re-
duction in lung volumes [13].
Chest radiographs are insensitive for detection of DIP 
and are reported to be normal in 3–22% of biopsy-proved 
cases. HRCT scan is sensitive for the detection and char-
acterization of interstitial lung diseases and may allow 
recognition and classification of the SR-ILD into distinct 
individual entities. HRCT findings of DIP show ground-
glass opacity, which may be peripheral, patchy, or diffuse 
in distribution. A peripheral subpleural and basal pre-
dominance of ground-glass opacity is most commonly 
seen [14].
Since the most significant histologic feature of DIP is 
intraalveolar accumulation of pigmented macrophages and 
not desquamated epithelial cells as previously thought, the 
term “desquamative” is a misnomer [2, 5]. Major features 
necessary to set diagnosis of DIP are: uniform involvement 
of lung parenchyma, marked accumulation of macro-
phages and light brown cytoplasmic pigmentation within 
macrophages. Minor (or secondary) features are: mild to 
moderate interstitial fibrosis, mild interstitial chronic in-
flammation, mild follicular hyperplasia and often a mildly 
increased numbers of eosinophils. The overall alveolar ar-
chitecture is usually well maintained, and honeycombing 
is minimal or absent, as well as fibroblastic foci (typical 
features of usual interstitial pneumonia – UIP) [2, 5].
However, clinical, radiologic, and histological features 
overlap among different SR-ILDs, and mixed patterns of 
the disease frequently coexist in the same patient [13]. 
The overlap is most significant between RB-ILD and DIP. 
Although RB-ILD is a closely related process, there are 
prognostic reasons for continuing to separate it from DIP 
when possible. RB-ILD most often presents between the 
third and sixth decades with dyspnea, persistent cough, 
while chest pain and weight loss are less frequent. Bilateral, 
predominantly basal inspiratory crackles are common, but 
clubbing is very rare. Patients with DIP are generally older 
than patients with RB-ILD, present in the fourth to sixth 
decade also with dyspnea, non-productive cough and, less 
frequently, fatigue and weight loss. Bilateral basal inspirato-
ry crackles are frequent, and clubbing is more often present 
than in patients with RB-ILD. In RB-ILD, both restrictive 
and obstructive abnormalities have been documented, 
while in DIP the ventilatory defect is consistently restric-
tive [15]. The key feature to differentiate the two disorders 
is histological finding. The distribution and extent of the 
lesions within the lung parenchyma are crucial for the exact 
diagnosis; macrophage accumulation is bronchiolocentric 
in RB-ILD producing centrilobular ground-glass opacity, 
and more diffuse in DIP producing widespread ground-
glass changes [16]. Also, it is very important to emphasize 
that DIP is usually a more aggressive process than RB-ILD      
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with no evidence that RB-ILD progresses to DIP [12]. 
Treatment (initially with corticosteroid therapy) is gen-
erally necessary in DIP but is rarely needed in RB-ILD, 
especially if smoking cessation is achieved [16]. The final 
diagnosis of SR-ILD and identification of the specific entity 
can be achieved only in cooperation with the clinician, the 
radiologist, and finally the pathologist.
Smoking cessation has the prime role in the treatment 
of DIP and may lead to disease regression [2]. Also, the 
cessation of exposure is necessary. In the series of five 
patients studied by Lougheed et al. [10] two patients im-
proved upon leaving the workplace and did not require 
steroid therapy, while two of the five patients returned to 
work and both experienced a relapse. Most patients show 
good response to oral corticosteroids and immunosup-
pressive therapy. With such treatment, most patients re-
main stable or improve, and complete recovery is possible 
[17, 18]. In contrast, Aubry et al. [1] showed that response 
to corticosteroids is not uniform as approximately 25% 
of patients may continue to progress despite treatment. 
According Kawabata et al. [3], corticosteroid therapy was 
effective early in the course of the disease, and long-term 
follow-up (mean 99 months) of 31 patients showed only 
one death due to the progression of the disease, but a long-
term follow-up of 14 patients (mean 125 months) five de-
veloped fibrosis and four lung cancer detected by HRCT 
scan, respectively. In a series of five patients, Knyazhitskiy 
et al. [19] suggest a possible role for macrolide antibiotics 
in patients with DIP refractory to steroid therapy. They de-
scribed the first case of DIP showing a rapid and dramatic 
response to treatment with clarithromycin.
Patients with DIP are thought to have a more favorable 
prognosis than other forms of idiopathic pulmonary fibro-
sis; however patients can progress to end stage disease, and 
may require lung transplantation as definitive treatment 
[16]. The 10-year survival rates are 70% [20].
REFERENCES
1.  Aubry MC, Wright JL, Myers JL. The pathology of smoking-related 
lung disease. Clin Chest Med. 2000; 21(1):11-35.
2.  Tazelaar HD, Wright JL, Churg A. Desquamative interstitial 
pneumonia. Histopathology. 2011; 58(4):509-16.
3.  Kawabata Y, Takemura T, Hebisawa A, Sugita Y, Ogura T, Nagai 
S, et al. Desquamative interstitial pneumonia may progress to 
lung fibrosis as characterized radiologically. Respirology. 2012; 
17(8):1214-21.
4.  Liebow AA, Steer A, Billingsley JG. Desquamative interstitial 
pneumonia. Am J Med. 1965; 39:369-404.
5.  Craig PJ, Wells AU, Doffman S, Rassl D, Colby TV, Hansell DM, et al. 
Desquamative interstitial pneumonia, respiratory bronchiolitis and 
their relationship to smoking. Histopathology. 2004; 45(3):275-82.
6.  Tubbs RR, Benjamin SP, Reich NE, McCormack LJ, Van Ordstrand HS. 
Desquamative interstitial pneumonitis. Cellular phase of fibrosing 
alveolitis. Chest. 1977; 72:159-65.
7.  Godbert B, Wissler MP, Vignaud JM. Desquamative interstitial 
pneumonia: an analytic review with an emphasis on aetiology. Eur 
Respir Rev. 2013; 22(128):117-23.
8.  Abraham JL, Hertzberg MA. Inorganic particles associated with 
desquamative interstitial pneumonia. Chest. 1981; 80:67-70.
9.  Moon J, Du Bois RM, Colby TV, Hansell DM, Nicholson AG. Clinical 
significance of respiratory bronchiolitis on open lung biopsy and 
its relationship to smoking-related interstitial lung disease. Thorax. 
1999; 54:1009-14.
10.  Lougheed MD, Roos JO, Waddell WR, Munt PW. Desquamative 
interstitial pneumonitis and diffuse alveolar damage in textile 
workers. Potential role of mycotoxins. Chest. 1995; 108:1196-200.
11.  King M, Jessurun J, Hertz M. Recurrence of desquamative interstitial 
pneumonia after lung transplantation. Am J Respir Crit Care Med. 
1997; 156(6):2003-5.
12.  Verleden GM. Recurrence of desquamative interstitial pneumonia 
after lung transplantation. Am J Respir Crit Care Med. 1998; 
157(4):1349-50.
13.  Selman M. The spectrum of smoking-related interstitial lung 
disorders: the never-ending story of smoke and disease. Chest. 
2003; 124(4):1185-7.
14.  Attili AK, Kazerooni EA, Gross BH, Flaherty KR, Myers JL, Martinez 
FJ. Smoking-related interstitial lung disease: radiologic-clinical-
pathologic correlation. RadioGraphics. 2008; 28(5):1383-96.
15.  Ryu JH, Myers JL, Capizzi SA, Douglas WW, Vassallo R, Decker  
PA. Desquamative interstitial pneumonia and respiratory 
bronchiolitis-associated interstitial lung disease. Chest. 2005; 
127(1):178-84.
16.  Katzenstein AL. Smoking-related interstitial fibrosis (SRIF), 
pathogenesis and treatment of usual interstitial pneumonia  
(UIP), and transbronchial biopsy in UIP. Modern Pathology. 2012; 
25:68-78.
17.  Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-
associated interstitial lung disease and its relationship to 
desquamative interstitial pneumonia. Mayo Clin Proc. 1989; 
64:1373-80.
18.  Hartman TE, Primack SL, Kang EY, Swensen SJ, Hansell 
DM, McGuinness G, et al. Disease progression in usual interstitial 
pneumonia: assessment with serial CT. Chest. 1996;  
110:378-82.
19.  Knyazhitskiy A, Masson RG, Corkey R, Joiner J. Beneficial response 
to macrolide antibiotic in a patient with desquamative interstitial 
pneumonia refractory to corticosteroid therapy. Chest. 2008; 
134:185-7.
20.  Katzenstein AL, Myers J. Idiopathic pulmonary fibrosis. Am J Respir 
Crit Care Med. 1998; 157(4):1301-15.  
606
  
doi: 10.2298/SARH1410602L
КРАТАК САДРЖАЈ
Увод Де  сква  ма  тив  на ин  тер  сти  ци  јал  на пне  у  мо  ни  ја је јед  на 
од нај  ре  ђих ин  тер  сти  ци  јал  них бо  ле  сти плу  ћа и нај  ре  ђи об-
лик ин  тер  сти  ци  јал  них бо  ле  сти плу  ћа удру  же  них с пу  ше  њем. 
Пр  ви пут су је опи  са  ли 1965. го  ди  не Ли  бов (Li e bow) и са  рад-
ни  ци. Хи  сто  ло  шки се од  ли  ку  је по  сто  ја  њем еози  но  фил  них 
ма  кро  фа  га уну  тар ал  ве  о  лар  них про  сто  ра ко  ји че  сто са  др  же 
фи  но гра  ну  ли  ран, све  тло  смеђ пиг  мент ко  ји се не бо  ји на 
хе  мо  си  де  рин. Зи  до  ви ал  ве  о  ла су уме  ре  но за  де  бља  ни услед 
умно  жа  ва  ња ве  зив  ног тки  ва и ин  фил  тро  ва  ни сред  ње гу-
стим ин  фил  тра  том лим  фо  ци  та.
При  каз бо  ле  сни  ка Наш бо  ле  сник је 56-го  ди  шњи му  шка-
рац, ду  го  го  ди  шњи пу  шач, с обо  стра  ним плућ  ним ин  фил-
тра  ти  ма не  по  зна  те ети  о  ло  ги  је и ви  ше  ме  сеч  ним те  го  ба  ма 
у ви  ду су  вог ка  шља и дисп  не  је. Те  сто  ви плућ  не функ  ци  је 
от  кри  ли су уме  рен ре  стрик  тив  ни по  ре  ме  ћај вен  ти  ла  ци  је и 
те  шко сма  ње  ње ка  па  ци  те  та ди  фу  зи  је. Ка  ко брон  хо  скоп  ска 
ис  пи  ти  ва  ња ни  су раз  ја  сни  ла по  ре  кло про  ме  на у плу  ћи  ма, 
из  вр  ше  на је отво  ре  на би  оп  си  ја до  њег ле  вог ре  жња и на 
осно  ву до  би  је  ног ма  те  ри  ја  ла па  то  хи  сто  ло  шки је по  ста  вље-
на ди  јаг  но  за де  сква  ма  тив  не ин  тер  сти  ци  јал  не пне  у  мо  ни  је. 
Бо  ле  сни  ку је за  бра  ње  но пу  ше  ње и пре  пи  са  на му је кор  ти-
ко  сте  ро  ид  на и ими  но  су  пре  сив  на те  ра  пи  ја. На по  след  њем 
кон  трол  ном пре  гле  ду, две го  ди  не на  кон по  ја  ве симп  то  ма, 
бо  ле  сник се до  бро осе  ћао, а ви  со  ко  ре  зо  лу  циј  ска ком  пју  те-
ри  зо  ва  на то  мо  гра  фи  ја груд  ног ко  ша по  ка  за  ла је по  вла  че  ње 
про  ме  на у плу  ћи  ма.
За  кљу  чак Иако се, као у при  ка  за  ном слу  ча  ју, ве  ћи  на бо-
ле  сни  ка опо  ра  ви на  кон ле  че  ња, код не  ких бо  ле  сни  ка се, 
упр  кос те  ра  пи  ји, ипак раз  ви  је про  гре  сив  на ире  вер  зи  бил  на 
фи  бро  за.
Кључ  не ре  чи: де  сква  ма  тив  на ин  тер  сти  ци  јал  на пне  у  мо  ни  ја; 
ин  тер  сти  ци  јал  на бо  лест плу  ћа; пу  ше  ње; пу  шач  ки ма  кро  фа-
ги; ин  тер  сти  ци  јал  на бо  лест плу  ћа удру  же  на с пу  ше  њем
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